Abstract Large retroperitoneal liposarcomas represent a unique situation and require a more aggressive surgical approach, including multiple resections for recurrences. We report a series of 5 cases of large retroperitoneal liposarcoma managed aggressively with surgical resection. All cases presented with lump and abdominal pain and diagnosis was established by Ultrasonography and CT scan. Post-operative course was uneventful and a median follow up of 3 years, all patients were free from recurrence.
teratoma. Histopathological examination revealed pleomorphic liposarcoma. The patient had a recurrence 5 years later in 2010. He was reexplored and all the masses were removed en-bloc. Figures 8, 9, 10 and 11.
Case 5
A 34-year-old male; on examination, he was found to have a large well-circumscribed, firm lump. Figures 12 and 13.
Discussion
Retroperitoneal liposarcoma is a malignant tumor of mesenchymal origin. It is one of the most common primary retroperitoneal neoplasms and affects middle-aged patients.
The most-common presenting symptom is a palpable abdominal mass, followed by a vague abdominal pain [1] . However, liposarcomas rarely involve the gastrointestinal tract [2] [3] [4] .
The gross appearance of the tumor depends on the histological type, degree of vascularity, presence of necrosis, and amount of mature fat and fibrous tissue. The tumor appears as a smooth, lobulated, or nodular mass in most instances. Recurrent tumors are not as well encapsulated.
The primary treatment option is resection, if possible [5, 6] . In our series, we followed the approach of the radical resection of the tumor instead of enucleation, assuming that we had to deal with a retroperitoneal tumor of an unknown pathology. However, local recurrence is common and occurs in 66% of patients. This has prompted the investigation of new combined-modality treatment approaches [7] . The most important prognostic factors are free margins, type of resection, age of the patient, and tumor histology.
Radiotherapy (RT) is indicated when the margins are not adequate or there is residual tumor or recurrence. RT is generally used as adjuvant treatment for palliation [8] and may also be applied in higher-grade, locally advanced retroperitoneal liposarcoma. Multi-institutional prospective randomized phase III trial (ACOSOG-Z9031) assessing the value of preoperative RT in patients with primary retroperitoneal soft tissue sarcoma is ongoing. Primary objective of this study is to find out whether preoperative RT will prolong survival without disease relapse. Little data are available for the use of combined RT and chemotherapy (CT). Decisions about adjuvant or neoadjuvant CT or RT are left to clinical judgment [9] [10] [11] .
A metastatic disease is hematogenous and the extent of metastases is related to the histological grade of the tumor. Local recurrence is the rule with all cell types and invariably with well-differentiated liposarcoma and its variants. Overall, 5-year survival rates are 60-70%. Excision followed by RT (60-70 Gy) results in a more significant reduction in local recurrence than does excision alone [12] . CT has not shown substantial benefits [13] . Myxoid/round cell liposarcoma is highly radio-and chemosensitive. It is selectively responsive to novel drugs, such as trabectedin, a DNA-binding agent. Differentiation between the subtypes of liposarcoma is important to indicate prognosis and, especially, to tailor treatment [14, 15] . Long-term results of two prospective trials showed favorable 5-year local recurrence-free (60%), disease-free (46%), and overall survival rates (61%) among patients who had complete oncological clearance (R0) or incomplete oncological clearance (R1) resection after preoperative RT for intermediate or high-grade retroperitoneal sarcoma [16] .
Recent advances have focused on oncogenesis and genomic profiling to identify subsets of liposarcoma, which follow separate molecular pathways. A well-differentiated liposarcoma has 12q rings and giant markers (chromosomal alteration), and the involved genes are HMGIC, CDK4, and MDM2 amplification with a frequency of >90% [17, 18] . The morphology of retroperitoneal liposarcoma has also been studied using optical coherence tomography. These could help in the future to evolve optimal treatment strategies [19] [20] [21] . 
